Roche is the latest company trying to tap into the highly lucrative weight-loss drug market by fast-tracking its own candidates.  The pharmaceutical giant said that its CT-388 drug is now entering the phase two trial and its CT-996 drug will be moving toward phase two trials next year "based on the encouraging data." Both come in the form of a pill rather than an injection."We are fast-tracking the clinical development of our obesity portfolio with the aim to bring these medications to patients faster than ...